Short answer · Medically reviewed summary · Last updated: 2026-05-08
Choroideremia is a rare, X-linked inherited retinal dystrophy first clinically described in the 19th century, with its genetic basis identified in the 1990s. The history of Choroideremia represents a significant evolution from early observational ophthalmology to groundbreaking gene therapy trials currently reshaping patient prognoses. When was Choroideremia first described? The condition now known as Choroideremia was first characterized in 1872 by the Dutch ophthalmologist Jacob Mauthner.
What is the history of Choroideremia?
History of Choroideremia: when and how it was discovered, and the milestones in research since, medically reviewed.
Choroideremia is a rare, X-linked inherited retinal dystrophy first clinically described in the 19th century, with its genetic basis identified in the 1990s. The history of Choroideremia represents a significant evolution from early observational ophthalmology to groundbreaking gene therapy trials currently reshaping patient prognoses.
When was Choroideremia first described?
The condition now known as Choroideremia was first characterized in 1872 by the Dutch ophthalmologist Jacob Mauthner. Initially, researchers struggled to distinguish the disease from other forms of retinal degeneration, such as retinitis pigmentosa. For decades, it was often misdiagnosed, as clinicians lacked the tools to visualize the specific loss of the choroid, retinal pigment epithelium, and photoreceptors that define Choroideremia.
How has our understanding of Choroideremia evolved?
The 20th century marked a shift from mere description to genetic mapping. In 1990, researchers identified the CHM gene on the X chromosome, which encodes the Rab escort protein-1 (REP1). This discovery confirmed that Choroideremia is inherited in an X-linked recessive pattern, primarily affecting males. Understanding that Choroideremia is caused by the absence of functional REP1 protein allowed for precise diagnostic genetic testing, replacing clinical guesswork with molecular confirmation.
What are the major milestones in Choroideremia treatment?
The field has transitioned from supportive care to active intervention. Key historical milestones include:
- 1990: Identification of the CHM gene, enabling accurate carrier testing.
- 2010s: The emergence of gene therapy trials aimed at delivering a functional copy of the CHM gene to retinal cells.
- Current Era: Utilization of advanced retinal imaging like Optical Coherence Tomography (OCT) to monitor disease progression and trial efficacy.
How has patient advocacy shaped the history of the disease?
Patient advocacy has been instrumental in accelerating research. Today, 96 people with Choroideremia have joined the DiseaseMaps community, sharing their experiences to foster global collaboration. This grassroots movement has helped bridge the gap between clinical researchers and those living with the condition, ensuring that the patient perspective remains central to future therapeutic developments.
Next steps
- Consult a retinal specialist or an ophthalmogeneticist to discuss the latest clinical trial eligibility.
- Connect with the 96 members of the Choroideremia community on DiseaseMaps.org to share insights and support.
- Review your family history and consider genetic counseling if you have a family history of retinal dystrophy.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Choroideremia
- Orphanet: Choroideremia (ORPHA166)
- Online Mendelian Inheritance in Man (OMIM): CHM gene (#300390)
- Choroideremia Research Foundation (CRF)
